Research Finds Actos Diabetes Drug Might Increase Bladder Cancer Risk

Posted on August 15, 2012

Actos, a drug meant to treat diabetes by curtailing the body’s resistance to insulin, might increase a patient’s risk of incurring bladder cancer if taken for a long period of time.  That finding comes from the University of Pennsylvania’s Perelman School of Medicine, who looked at about 60,000 patients, some taking a thiazolidinedione (TZD) like Actos and some taking a sulfonylurea drug.  Out of 100,000 patients, 170 TZD patients are estimated to get bladder cancer after half a decade, compared with only 60 for sulfonylurea patients.

For more about this finding, click here.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.
*Required Fields